GlobeNewswire

Cisco Continues To Evolve Its Routing Portfolio for Mass-Scale Networking to Meet Carriers' Needs

Dela

Global Service Providers Rely on Cisco for Networking Innovation

PARIS, MPLS+SDN+NFV World Congress, April 09, 2018 (GLOBE NEWSWIRE) -- The explosive growth in IP traffic continues to create opportunities and challenges for service providers who are focused on delivering compelling services to retain and grow their customer base. Changing network traffic patterns show 35% of Internet traffic will be carried metro-to-metro in 20211, up from 22% in 2016, with more devices connected to the network. As a result, service providers are adjusting their network routing plans to distribute features further to the edge for improved performance.

Cisco is leading with innovation that allows carriers to transform their networks to deal with the explosion in traffic growth and change in traffic patterns led by mobile apps and connections, IoT, video, 5G and more. Cisco has responded with innovative hardware, software and security additions to its service provider routing platform to offer a mix of options for customers needing feature-rich platforms with higher density to support intense bandwidth demands.

Powered by Cisco IOS XR, the industry's most trusted network operating system, this expanded portfolio offers an abundance of features that help to simplify operations such as zero-touch deployment, advanced programmability and model-driven telemetry.

Routing hardware additions include:

  • Cisco NCS 500 Series: Featuring a unified, single operating system (Cisco IOS XR), it addresses converged wireline and wireless 5G-ready requirements for fronthaul, midhaul and backhaul, and future evolutions of carrier ethernet networks; It addresses various bandwidth needs ranging from 1 Gigabyte to 100 Gbps interfaces in small form factors.
  • Cisco ASR 9901:  Also featuring a unified, single operating system (Cisco IOS XR), it supports applications such as distributed provider edge, Internet peering, metro aggregation and broadband network gateway (BNG) in a space-optimized platform; It delivers 900 Gbps of throughput while also providing flexibility in terms of port speeds ranging from 1 to 100 Gbps with industry-leading MACsec encryption support across all ports.
  • Cisco NCS 5500 Series: New components include:
    • Two fixed chassis supporting 24 and 36 100GE ports
    • A 36 100GE ports line card targeted at high-density core, mobile backhaul and data center interconnect use cases; Offers flexible port configuration supporting 10G/25G/40G and 100G per port with enhanced scale capabilities (external TCAM)
    • A compact 2RU router targeted at high-density metro aggregation, mobile backhaul networks and long-haul connectivity use cases; Delivers maximum flexibility with the support of Modular Port Adapters (MPA) with options of different port types and MACsec encryption support.

Routing software additions include:

  • Segment Routing: Offers service providers more control over Internet traffic by delivering a unified transport fabric across aggregation, edge, core and data center network domains with unmatched simplicity, resiliency and scalability; With Segment Routing Flexible Algorithm, a new addition to the Cisco Segment Routing Traffic Engineering toolkit, service providers can:
    • Optimize the same physical network infrastructure along various dimensions such as low-latency, bandwidth or path disjointness.
    • Custom fit 5G network slices to specific applications
  • Ethernet VPN (EVPN): Cisco is now offering seamless integration with Virtual Private LAN Service (VPLS), helping service providers speed up migration from VPLS to EVPN as another method to provide Ethernet-based multipoint to multipoint communication over IP or MPLS networks; EVPN offers improved scalability, optimal forwarding and helps prevent traffic floods.

With more applications and devices connected to the network, security threats are significantly increasing. Cisco is securing the service provider network at three levels to help protect against current and future threats:

  • Hardware: Ensuring platform integrity while in transit from factories to customer premises
  • Software: Providing secure boot and integrity check to ensure the software that is installed is genuine and unmodified
  • Network: Offering MACsec hardware support to encrypt traffic between network nodes as well as scalable anti-DDoS

"Cisco continues to drive innovation in service provider routing to help our customers uplevel their architectures and be one step ahead in managing their network traffic demands," said Jonathan Davidson, senior vice president and general manager, Service Provider Networking, Cisco. "As the majority of our customers get ready for 5G, our unmatched portfolio of options offers intent-based networking practices to enable networks to self-heal without service interruptions."

"We needed a future-proof networking platform to support high-density 100G interfaces with optimized power consumption to deliver ultrabroadband connections," said Marco Arioli, senior manager of Network Engineering at Fastweb."With the Cisco NCS 5500 platform, we are getting the scale and power efficiency we were looking for and are reaping the benefits of a seamless and unified software fabric, powered by Cisco IOS XR to accelerate our time-to-market and streamline adoption of new services."

"We are building a widespread and efficient network to speed broadband adoption across Italy," said Domenico Angotti, head of Engineering at Open Fiber. "We are deploying Cisco NCS 5500 in our national Points of Presence to give us the performance and high-density of 100GE interfaces with lower power consumption, and a rich set of YANG data models that are essential to advanced network programmability."

"Shentel is evolving its network to support 100G interfaces to keep pace with the growth of Internet services and lay the foundation for 5G services," said Edward McKay, senior vice president, Wireline and Engineering, Shentel. "Cisco IOS XR and segment routing technology is helping to simplify our operations with an SDN architecture designed to support multi-path routing with extreme scale across our core networks."

Cisco is leading the disruption in the industry with its technology innovations in systems; silicon; software and security; and its unrivalled expertise in mass-scale networking, automation, optical, optics, cable access, video, and mobility. Combining these capabilities with Cisco's portfolio of go-to-market security, collaboration, IoT, and professional services, we enable service providers, media and web companies to reduce cost and complexity, help secure their networks, and grow revenue.

Supporting Resources

RSS Feed for Cisco:  http://newsroom.cisco.com/dlls/rss.html

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.

Press Contact
Sara Cicero, Service Provider PR, Cisco, stutzes@cisco.com

____________________________

1 Cisco Visual Networking Index Forecast 2016-2021




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum